Ocumetics Director and CEO, Dean Burns, walks through relevant topics including:
- Successful manufacture of the Ocumetics IOL
- Remaining steps to first-in-human study
- Q&A session
Thanks to everyone who joined us for the Webinar. It was an amazing turnout, and it was great to hear your questions and comments. We look forward to hosting more webinars in the future!
https://youtu.be/U0GrNVtLNSc?si=lZYKlYUM2tH-KDjJ
Calgary, Alberta – TheNewswire – December 9, 2025 – Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in next generation ophthalmic technology, is pleased to announce that Medicel AG (“Medicel”), a global leader in ophthalmic device delivery systems, has further modified its lens delivery technology in response to
Dear Investors, I have received several inquiries about our October 8th press release. It marks an exciting and historic milestone for Ocumetics. The patients selected for our first clinical group entered the study with very poor functional vision due to cataracts and were struggling to see clearly at distance. One month following cataract surgery and
Ocumetics Director and CEO, Dean Burns covers important updates on our first-in-human (FIH) study and what lies ahead. Topics include: Encouraging outcomes from initial surgeries Next steps to complete the FIH study Live Q&A session with Dean Burns https://youtu.be/rWQnOaq6sVE
